Endogenous corticotropin releasing factor regulates adrenergic and opioid receptors

Peptides

Volumn 23, Issue 12, 2002, Pages 2177-2180

  Rothman, Richard B ^a   Vu, Nga ^a   Xu, Heng ^a   Baumann, Michael H ^a   Lu, Yi Feng ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Adrenergic receptors; Corticotropin releasing factor (CRF); Opioid receptors

Indexed keywords

ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; CORTICOTROPIN RELEASING FACTOR; IMMUNOGLOBULIN G; OPIATE RECEPTOR;

ANIMAL TISSUE; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR DENSITY; REGULATORY MECHANISM; UPREGULATION;

ANIMALS; CORTICOTROPIN-RELEASING HORMONE; IMMUNOGLOBULIN G; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC; RECEPTORS, OPIOID;

EID: 0036952987     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(02)00245-0     Document Type: Article

References (22)

1. Amin-Hanjani S, Chapman PH. Cerebrospinal fluid and its abnormalities. In: Encyclopedia of life sciences. Nature Publishing Group; 2001. p. 1-8. http://www.els.net.
2. Amir S. Involvement of endogenous opioids with forced swimming-induced immobility in mice. Physiol. Behav. 28:1982;249-251.
3. Danguir J. Food intake in rats is increased by intracerebroventricular infusion of the somatostatin analogue SMS 201-995 and is decreased by somatostatin antiserum. Peptides. 9:1988;211-213.
4. 5]enkephalin binding sites by different mechanisms Neuropharmacology. 27:1988;965-974.
5. Goodman C.B., Heyliger S.O., Emilien B., Partilla J.S., Yang H.Y., Lee C.H.et al. Regulation of mu binding sites after chronic administration of antibodies directed against specific anti-opiate peptides. Peptides. 19:1998;1703-1709.
6. Goodman C.B., Heyliger S.O., Emilien B., Partilla J.S., Yang H.Y., Lee C.H.et al. Chronic exposure to antibodies directed against anti-opiate peptides alter delta-opioid receptor levels. Peptides. 20:1999;1419-1424.
7. Grijalba B., Callado L.F., Javier Meana J., Garcia-Sevilla J.A., Pazos A. Alpha 2-adrenoceptor subtypes in the human brain: a pharmacological delineation of [3H]RX-821002 binding to membranes and tissue sections. Eur. J. Pharmacol. 310:1996;83-93.
8. 35S ]GTP-gamma-S binding sites and their response to chronic morphine treatment: a binding surface analysis Brain Res. Bull. 51:2000;357-362.
9. Koike K., Takayanagi I. Characteristics of [3H]CGP12177 binding sites at beta 2- and beta 3-adrenoceptors in the guinea pig taenia caecum. Gen. Pharmacol. 28:1997;73-76.
10. Meltzer HY, Lowy MT. The serotonin hypothesis of depression. In: Meltzer HY, editor. Psychopharmacology: the third generation of progress. New York: Raven Press; 1987. p. 513-26.
11. Owens M.J., Nemeroff C.B. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol. Rev. 43:1991;425-473.
12. Paxinos G. The rat brain in stereotaxic coordinates. New York: Academic Press; 1982.
13. Reul J.M., Holsboer F. Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr. Opin. Pharmacol. 2:2002;23-33.
14. Rothman R.B. Binding surface analysis: an intuitive yet quantitative method for the design and analysis of ligand binding studies. Alcohol Drug. Res. 6:1985;309-325.
15. 5]enkephalin: evidence for two mu binding sites Eur. J. Pharmacol. 160:1989;71-82.
16. 125I ]RTI-55 in membranes prepared from human, monkey and guinea pig caudate Synapse. 28:1998;322-338.
17. Sarnyai Z., Biro E., Penke B., Telegdy G. The cocaine-induced elevation of plasma corticosterone is mediated by endogenous corticotropin-releasing factor (CRF) in rats. Brain Res. 589:1992;154-156.
18. Sastre M., Garcia-Sevilla J.A. Alpha 2-adrenoceptor subtypes identified by [3H]RX821002 binding in the human brain: the agonist guanoxabenz does not discriminate different forms of the predominant alpha 2A subtype. J. Neurochem. 63:1994;1077-1085.
19. Schulz C., Lehnert H. Activation of noradrenergic neurons in the locus coeruleus by corticotropin-releasing factor. A microdialysis study. Neuroendocrinology. 63:1996;454-458.
20. Smagin G.N., Swiergiel A.H., Dunn A.J. Corticotropin-releasing factor administered into the locus coeruleus, but not the parabrachial nucleus, stimulates norepinephrine release in the prefrontal cortex. Brain Res. Bull. 36:1995;71-76.
21. Tsuchihashi H., Nagotomo T., Imai S. Selectivity of bunitrolol for beta 1- and beta 2-adrenergic receptors and 5HT1B-receptors: assessment by biphasic Scatchard plots and biphasic displacement curve analysis with 125I-iodocyanopindolol and 3H-CGP12177. Jpn. J. Pharmacol. 50:1989;93-100.
22. Valentino R.J., Van Bockstaele E. Opposing regulation of the locus coeruleus by corticotropin-releasing factor and opioids. Potential for reciprocal interactions between stress and opioid sensitivity. Psychopharmacology. 158:2001;331-342.